InflammamiR-146a and -155 Plasma Levels are Associated with Clinical Efficacy of Risankizumab Treatment in Psoriatic Patients: Pilot Study
Abstract Introduction The key role of microRNAs (miRNAs) in the pathogenesis of psoriasis has been extensively discussed in the literature. Increasing evidence suggests that the analysis of miRNA levels may constitute an innovative approach for exploring the clinical efficacy of anti-inflammatory th...
Saved in:
Main Authors: | Federico Diotallevi (Author), Giulia Matacchione (Author), Giovanni Marco d'Agostino (Author), Helena Gioacchini (Author), Anna Campanati (Author), Jacopo Sabbatinelli (Author), Fabiola Olivieri (Author), Annamaria Offidani (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2023-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment of Moderate-to-Severe Psoriasis in the Presence of Kaposi's Varicelliform Eruption
by: Anna Campanati, et al.
Published: (2019) -
New and Old Horizons for an Ancient Drug: Pharmacokinetics, Pharmacodynamics, and Clinical Perspectives of Dimethyl Fumarate
by: Paolinelli Matteo, et al.
Published: (2022) -
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials
by: Kenneth B. Gordon, et al.
Published: (2024) -
Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023) -
Deregulation of MicroRNA-146a and 155 expression levels might underlie complicated pregnancy in Toxoplasma Gondii seronegative women
by: Marwa M. Naguib, et al.
Published: (2024)